Gold Michael, Bridges Tancy M, Bradshaw Virginia Lee, Boring Molly
Gold Skin Care Center, 2000 Richard Jones Road, Suite 220, Nashville, TN 37215, USA.
J Drugs Dermatol. 2004 Jan-Feb;3(1 Suppl):S32-5.
Hidradenitis suppurativa (HS) is a chronic, often suppurative skin condition which affects primarily apocrine glands. A variety of therapies have been used to treat HS, often with unsatisfactory results. Photodynamic therapy (PDT), utilizing topical 20% 5-aminolevulinic acid (ALA) is being used to treat a variety of dermatologic skin concerns, including photorejuvenation and associated actinic keratoses, and acne vulgaris, and other skin tumors.
The purpose of these case reports is to evaluate the effectiveness of ALA-PDT in treating recalcitrant cases of HS.
Four patients, not responding to standard HS therapy, underwent short-contact ALA-PDT therapy utilizing a blue light for activation. One to two week intervals between therapies was utilized for 3-4 total treatments and follow-up was for 3 months following the last treatment.
All four of the patients tolerated the therapies well. Clinical improvements from 75-100% were noted n 11 of the patients. No adverse effects were seen during the treatments. The treatments were pain free and there was no downtime associated with these ALA-PDT treatments.
HS is a chronic disease which most dermatologists find difficult to treat. The use of ALA-PDT is finding an ever-expanding role in dermatology. These case studies support the use of ALA-PDT in cases of HS. Although all advertising material is expected to conform to ethical and medical standards, inclusion in this publication does not constitute a guarantee or endorsement by the Journal or its staff of the quality or value of such products or of the claims of any manufacturer.
化脓性汗腺炎(HS)是一种主要累及顶泌汗腺的慢性、常伴有化脓的皮肤疾病。多种疗法已被用于治疗HS,但效果往往不尽人意。光动力疗法(PDT),使用局部20%的5-氨基酮戊酸(ALA),正被用于治疗多种皮肤问题,包括光嫩肤及相关的光化性角化病、寻常痤疮以及其他皮肤肿瘤。
这些病例报告的目的是评估ALA-PDT治疗HS难治性病例的有效性。
4例对标准HS治疗无反应的患者接受了利用蓝光激活的短接触ALA-PDT治疗。治疗间隔为1至2周,共进行3至4次治疗,最后一次治疗后随访3个月。
所有4例患者对治疗耐受性良好。11例患者的临床改善率为75%至100%。治疗期间未见不良反应。治疗过程无痛,且这些ALA-PDT治疗未导致停工期。
HS是一种大多数皮肤科医生认为难以治疗的慢性疾病。ALA-PDT在皮肤科的应用正发挥着越来越广泛的作用。这些病例研究支持在HS病例中使用ALA-PDT。尽管所有广告材料都应符合道德和医学标准,但本出版物收录并不构成该期刊或其工作人员对这类产品的质量或价值或任何制造商声明的保证或认可。